Chronic Plaque Psoriasis Market Report 2026

Chronic Plaque Psoriasis Market Overview

• Chronic Plaque Psoriasis market size has reached to $22.26 billion in 2025 • Expected to grow to $30.99 billion in 2030 at a compound annual growth rate (CAGR) of 6.8% • Growth Driver: Impact Of Immune System Dysfunction On Chronic Plaque Psoriasis Treatment Demand • Market Trend: Advancements In IL-17A And IL-17F Inhibitor Therapies For Plaque Psoriasis Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Chronic Plaque Psoriasis Market?

Chronic plaque psoriasis is a persistent, inflammatory skin condition characterized by the formation of well-defined, raised, red patches covered with silvery-white scales. These plaques most commonly appear on the scalp, elbows, knees, and lower back but can occur anywhere on the body. It is an autoimmune disorder in which the immune system triggers an accelerated turnover of skin cells, leading to their buildup on the surface. The main drug classes of chronic plaque psoriasis are biologics and small-molecule drugs. Biologics are advanced medications derived from living organisms that target specific components of the immune system to treat various diseases. It is available as injectables, oral, and topical and is distributed through hospital pharmacies, online pharmacies, and retail pharmacies.

What Is The Chronic Plaque Psoriasis Market Growth Forecast?

The chronic plaque psoriasis market size is expected to see strong growth in the next few years. It will grow to $30.99 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to increasing development of next-generation biologics, rising adoption of oral immunomodulators, expansion of precision dermatology approaches, growing focus on patient-centric treatment plans, increasing investment in autoimmune disease research. Major trends in the forecast period include increasing adoption of biologic therapies, rising use of targeted small molecule drugs, growing focus on personalized dermatology care, expansion of oral treatment options, enhanced emphasis on long-term disease control.

What Is The Driver Of The Chronic Plaque Psoriasis Market?

The increasing cases of immune system dysfunction are expected to propel the growth of the chronic plaque psoriasis market going forward. Immune system dysfunction refers to a state where the immune system fails to operate effectively, leading to increased susceptibility to infections, autoimmune diseases, and cancer. The increasing cases of immune system dysfunction are attributed to factors such as genetic predispositions, environmental triggers, malnutrition, chronic stress, and the rising prevalence of autoimmune diseases and infections like HIV. Chronic plaque psoriasis treatment is required to regulate immune system dysfunction, as the immune system mistakenly triggers an overproduction of skin cells, leading to inflammation and the formation of plaques. For instance, in February 2024 according to the Arthritis Australia is a Australia-based non-profit organization In 2025, an estimated 212,136 males and 362,137 females are projected to have rheumatoid arthritis (RA), with the numbers expected to rise by 2040 to approximately 280,040 males and 479,828 females. Therefore, the increasing cases of immune system dysfunction are driving the growth of the chronic plaque psoriasis industry.

Key Players In The Global Chronic Plaque Psoriasis Market

Major companies operating in the chronic plaque psoriasis market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Bristol‑Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Dr Reddy’s Laboratories, Innovent Biologics Inc., Bio‑Thera Solutions, Celgene Corporation, Arcutis Biotherapeutics, LEO Pharma A/S, Sun Pharmaceutical Industries Ltd, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Biocon Ltd, Stiefel Laboratories Inc, Regeneron Pharmaceuticals, Sanofi S.A., GSK plc, Merck & Co. Inc., UCB S.A., Roche Holding AG, Evelo Biosciences Inc, Biogen Inc.

Global Chronic Plaque Psoriasis Market Trends and Insights

Major companies operating in the chronic plaque psoriasis market are focusing on developing innovative treatments, such as IL-17A and IL-17F inhibitors, to gain advancement in the treatment of chronic plaque psoriasis. IL-17A and IL-17F inhibitors are targeted biologic therapies that block interleukin-17A and interleukin-17F, pro-inflammatory cytokines involved in the immune response, to reduce inflammation in autoimmune diseases like chronic plaque psoriasis. For instance, in October 2023, UCB S.A., a Belgium-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved BIMZELX (bimekizumab-bkzx) for adults with moderate to severe plaque psoriasis who are eligible for systemic therapy or phototherapy. Bimekizumab is the first approved medication for psoriasis specifically designed to target and inhibit interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines involved in inflammatory processes. Its approval was based on evidence from three Phase 3 multicenter trials BE READY, BE VIVID, and BE SURE which collectively assessed its safety and efficacy in 1,480 patients with moderate to severe plaque psoriasis.

What Are Latest Mergers And Acquisitions In The Chronic Plaque Psoriasis Market?

In October 2024, Organon, a US-based healthcare company, acquired Dermavant Sciences Ltd. for an undisclosed amount. This acquisition enhances Organon’s dermatology portfolio with the addition of VTAMA (tapinarof) Cream, 1%, an innovative dermatologic therapy. VTAMA Cream is a novel, nonbiologic, non-steroidal topical treatment approved by the U.S. Food and Drug Administration (FDA) for managing mild, moderate, and severe plaque psoriasis in adults. Dermavant Sciences Ltd. is a US-based company focused on developing and commercializing innovative therapies in the field of immunodermatology.

What Defines the Chronic Plaque Psoriasis Market?

The chronic plaque psoriasis market consists of revenues earned by entities by providing services such as medication delivery services, customized treatment plans, and genetic and biomarker testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic plaque psoriasis market also includes sales of vitamin D analogues, combination topicals, phosphodiesterase-4 inhibitors, and janus kinase inhibitors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Chronic Plaque Psoriasis Market Report 2026?

The chronic plaque psoriasis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the chronic plaque psoriasis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.